Journal article
The potential of peptide immunotherapy in allergy and asthma
Abstract
Allergic conditions contribute significantly to the burden of chronic disease in the industrialized world. Current treatments offer varying degrees of palliation. The sole proven disease-modifying strategy, specific or whole-allergen immunotherapy, is limited because of the associated risk of systemic adverse effects, such as anaphylaxis. Short, linear allergen-derived peptides, corresponding to T cell epitopes, offer the possibility of a safer …
Authors
Ali FR; Kay AB; Larché M
Journal
Current Allergy and Asthma Reports, Vol. 2, No. 2, pp. 151–158
Publisher
Springer Nature
Publication Date
March 2002
DOI
10.1007/s11882-002-0010-5
ISSN
1529-7322